Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia

Blood

Volumn 94, Issue 7, 1999, Pages 2230-2235

  Estey, Elihu H ^a   Giles, Francis J ^a   Kantarjian, Hagop ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Freireich, Emil J ^a   Lopez Berestein, Gabriel ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IDARUBICIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0033215452     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2230.419k05_2230_2235     Document Type: Article

References (19)

1. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10, 1994
2. Jurcic JG, Miller WH, DeBlasio A, Scheinberg DA, Warrell RP Jr: Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia (APL). Blood 88:635a, 1996 (suppl 1, abstr)
3. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340:1437, 1992
4. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299, 1992
5. Adamson P: Pharmacokinetics of all-trans-retinoic acid: Clinical implications in acute promyelocytic leukemia. Semin Hematol 31:14, 1994 (suppl 5)
6. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L: All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 6:64, 1992
7. Degos L, Dombret H, Chomienne C, Daniel M-T, Micléa J-M, Chastang C, Castaigne S, Fenaux P: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995
8. Delva L, Comic M, Balitrand N, Guidez F, Micléa J-M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175, 1993
9. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Tallman MS, Wiernik PH, Gallagher RE: Retinoic acid receptor alpha (RARα)-region mutations in the PML-RARα fusion gene of acute promyelocytic leukemia (APL) patients after relapse from all-trans retinoic acid (ATRA) therapy. Blood 90:415a, 1997 (suppl 1, abstr)
10. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G: Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87:3650, 1996
11. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483, 1997
12. Thall PF, Simon R, Estey EH: New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 14:296, 1995
13. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1689, 1993
14. Huang M, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Zhoa L, Gu L-J, Wang Z-Y: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
15. Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C, Wang W, Zu W-Y, Yao X-Z, Ling B-J: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413, 1991
16. Sun G-L, Zhou R-F, Wu W, Jiang G-S: Follow-up of 524 APL patients after CR induced by ATRA. Leukemia 8:1082, 1994
17. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli: AIDA (All-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malatti Ematologiche Maligne dell' Adulto (GIMEMA) Pilot Study. Blood 88:1390, 1996
18. Fenaux P, Chastang C, Sanz M, Thomas X, Dombret H, Link H, Guerci A, Fegueux N, San Miguel J, Rayon C, Zittoun R, Gardin C, Maloisel F, Fey M, Travade P, Reiffers J, Stamatoulas A, Stoppa AM, Caillot D, Lefrére F, Hayat M, Castaigne S, Chomienne C, Degos L: ATRA followed by chemotherapy (CT) vs ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: First interim results of APL 93 trial. Blood 90:122a, 1997 (suppl 1, abstr)
19. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997